GB0715939D0 - Method of treatment of duchenne muscular dystrophy - Google Patents

Method of treatment of duchenne muscular dystrophy

Info

Publication number
GB0715939D0
GB0715939D0 GBGB0715939.5A GB0715939A GB0715939D0 GB 0715939 D0 GB0715939 D0 GB 0715939D0 GB 0715939 A GB0715939 A GB 0715939A GB 0715939 D0 GB0715939 D0 GB 0715939D0
Authority
GB
United Kingdom
Prior art keywords
treatment
muscular dystrophy
duchenne muscular
duchenne
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0715939.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Vastox PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vastox PLC filed Critical Vastox PLC
Priority to GBGB0715939.5A priority Critical patent/GB0715939D0/en
Publication of GB0715939D0 publication Critical patent/GB0715939D0/en
Priority to CA002685605A priority patent/CA2685605A1/en
Priority to TW097131027A priority patent/TW200914430A/en
Priority to CN2008800160060A priority patent/CN102036972A/en
Priority to PCT/EP2008/006720 priority patent/WO2009021750A2/en
Priority to JP2010520500A priority patent/JP2010535831A/en
Priority to MX2009012203A priority patent/MX2009012203A/en
Priority to AU2008286326A priority patent/AU2008286326A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65324—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
GBGB0715939.5A 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy Ceased GB0715939D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0715939.5A GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy
CA002685605A CA2685605A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
TW097131027A TW200914430A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
CN2008800160060A CN102036972A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
PCT/EP2008/006720 WO2009021750A2 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
JP2010520500A JP2010535831A (en) 2007-08-15 2008-08-14 Treatment of Duchenne muscular dystrophy
MX2009012203A MX2009012203A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy.
AU2008286326A AU2008286326A1 (en) 2007-08-15 2008-08-14 Treatment of Duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715939.5A GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0715939D0 true GB0715939D0 (en) 2007-09-26

Family

ID=38566449

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0715939.5A Ceased GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy

Country Status (8)

Country Link
JP (1) JP2010535831A (en)
CN (1) CN102036972A (en)
AU (1) AU2008286326A1 (en)
CA (1) CA2685605A1 (en)
GB (1) GB0715939D0 (en)
MX (1) MX2009012203A (en)
TW (1) TW200914430A (en)
WO (1) WO2009021750A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
US9246108B2 (en) * 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
AU2017243198A1 (en) * 2016-03-30 2018-11-22 Summit (Oxford) Limited Composition for the treatment of duchenne muscular dystrophy
CN113264894A (en) * 2021-05-24 2021-08-17 陕西维世诺新材料有限公司 Benzoxazole derivative and preparation method thereof
WO2023175010A1 (en) 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Use of bazedoxifene for increasing muscle survival

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
WO2003045929A1 (en) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US20050260126A1 (en) * 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
EP1581217A4 (en) * 2002-11-01 2007-07-11 Merck & Co Inc Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
NZ570625A (en) * 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
TW200914430A (en) 2009-04-01
CA2685605A1 (en) 2009-02-19
WO2009021750A2 (en) 2009-02-19
AU2008286326A1 (en) 2009-02-19
CN102036972A (en) 2011-04-27
MX2009012203A (en) 2009-12-18
WO2009021750A3 (en) 2014-02-20
JP2010535831A (en) 2010-11-25

Similar Documents

Publication Publication Date Title
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of duchenne muscular dystrophy
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
ZA200806630B (en) Method of treatment for muscular dystrophy
PT2170396T (en) Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
EP2350641A4 (en) Method of treatment
ZA200806986B (en) Treatment of duchenne muscular dystrophy
GB0715937D0 (en) Method of treatment og duchenne muscular dystrophy
EP2389180A4 (en) Methods of treating muscular dystrophies
PL2576582T3 (en) Treatment of muscular dystrophy
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0602767D0 (en) Treatment of muscular dystrophy
GB0614690D0 (en) Method of treatment of duchenne muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0617737D0 (en) Treatment of duchenne muscular dystrophy
GB0617739D0 (en) Treatment of duchenne muscular dystrophy
GB0623985D0 (en) Treatment of duchenne muscular dystrophy
GB0617740D0 (en) Treatment of duchenne muscular dystrophy
GB0623984D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)